Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.atg.2014.09.001 http://scihub22266oqcxt.onion/10.1016/j.atg.2014.09.001 C4888825!4888825!27294020     free     free     free Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Appl+Transl+Genom 2014 ; 3 (4): 86-9 Nephropedia Template TP {{tp|p=27294020|t=2014. The paradigm shift to an ?open? model in drug development |pdf=|usr=}}{{27294020}} gab.com Text The paradigm shift to an open model in drug development JO: Appl Transl Genom http://www.kidney.de/pget.php?&tw=1&pmid=27294020 #FOAvip The rising cost of healthcare, the rising cost for drug development, the patent cliff for Big pharma, shorter patent protection, decrease reimbursement, and the recession have made it more difficult for the pharmaceutical and biotechnology industry to develop drugs. Due to the unsustainable amount of time and money in developing a drug that will have a significant return on investment (ROI) it has become hard to sustain a robust pipeline. The industry is transforming its business model to meet these challenges. In essence a paradigm shift is occurring; the old ?closed? model is giving way to a new ?open? business model. Twit Text FOAVip The paradigm shift to an open model in drug development ????Appl Transl Genom http://www.kidney.de/pget.php?&tw=1&pmid=27294020 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=27294020 #FOAvip English Wikipedia <ref>{{Cite pmid|27294020}}</ref> The paradigm shift to an ?open? model in drug development #MMPMID27294020 Au R Appl Transl Genom 2014[Dec]; 3 (4): 86-9 PMID27294020show ga The rising cost of healthcare, the rising cost for drug development, the patent cliff for Big pharma, shorter patent protection, decrease reimbursement, and the recession have made it more difficult for the pharmaceutical and biotechnology industry to develop drugs. Due to the unsustainable amount of time and money in developing a drug that will have a significant return on investment (ROI) it has become hard to sustain a robust pipeline. The industry is transforming its business model to meet these challenges. In essence a paradigm shift is occurring; the old ?closed? model is giving way to a new ?open? business model. äThe paradigm shift to an ?open? model in drug development (epmc).pdf DeepDyve Pubget Overpricing